Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium

Journal of Clinical and Aesthetic Dermatology

Volumn 5, Issue 9, 2012, Pages 37-46

  Bernardo, Sebastian G ^a   Emer, Jason J ^a   Burnett, Mark E ^a   Gordon, Marsha ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CELECOXIB; CORTICOSTEROID; DOCETAXEL; FOLIC ACID; HYDROMORPHONE; OXYCODONE; PALONOSETRON; PAMIDRONIC ACID; PREDNISONE;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CELLULITIS; CHRONIC PAIN; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DERMATITIS; DIARRHEA; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FOOT PAIN; HAND PAIN; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; LUNG NON SMALL CELL CANCER; MALE; MEDICAL HISTORY; METASTASIS; REVIEW; SINGLE DRUG DOSE;

EID: 84866850026     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Martínez-Lavín M, Matucci-Cerinic M, Jajic I, et al. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol. 1993;20(8):1386-1387. (Pubitemid 23310996)
2. Nguyen S, Hojjati M. Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy. Clin Rheumatol. 2011;30:7-13.
3. Langford CA, Mandell BF. In: Longo, et al, eds. Harrison's Principles of Internal Medicine. 18th ed. New York, New York: McGraw-Hill Medical; 2012:2856-2858.
4. Hammarsten JF, O'Leary J. The features and significance of hypertrophic osteoarthropathy. Arch Intern Med. 1957;99(3):431-441.
5. Amital H, Applbaum YH, Vasiliev L, et al. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol. 2004; 23:330-332. (Pubitemid 39193789)
6. Mauricio O, Francis L, Athar U, et al. Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates. J Thorac Oncol. 2009;4(2):260-262.
7. Loscalzo J. In: Longo, et al, eds. Harrison's Principles of Internal Medicine. 18th ed. New York, New York: McGraw-Hill Medical; 2012:290.
8. Alves AP, Holanda Filha JG, Jeronimo FT. Eyelid ptosis associated with pachydermoperiostosis: case report. Arq Bras Oftalmol. 2005;68(3):401-404. (Pubitemid 41702388)
9. Arinci A, Tümerdem B, Karan MA, et al. Ptosis caused by pachydermoperiostosis. Ann Plast Surg. 2002;49(3):322-325. (Pubitemid 35006570)
10. Martinez-Lavin M, Vargas A, Rivera-Viñas M. Hypertrophic osteoarthropathy: a palindrome with a pathogenic connotation. Curr Opin Rheumatol. 2008;20(1):88-91. (Pubitemid 351339437)
11. Coury, C. Hippocratic fingers and hypertrophic osteoarthropathy. A study of 350 cases. Br J Dis Chest. 1960;54:202-209.
12. Jamieson A. The causes of finger clubbing: a list worth learning. Am J Med. 2011;124(7):e1-e3.
13. Armstrong DJ, McCausland EM, Wright GD. Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): two cases presenting as acute inflammatory arthritis. Description and review of the literature. Rheumatol Int. 2007;27(4):399-402. (Pubitemid 46122286)
14. Chen YC, Tiu CM, Bai LY, et al. Hypertrophic pulmonary osteoarthropathy associated with disease progression in renal cell carcinoma. J Chin Med Assoc. 2003;66(1):63-66.
15. Dickinson CJ. The aetiology of clubbing and hypertrophic osteoarthropathy. Eur J Clin Invest. 1993;23(6):330-338. (Pubitemid 23168554)
16. Shneerson JM. Digital clubbing and hypertrophic osteoarthropathy: the underlying mechanisms. Br J Dis Chest. 1987;75(2):113-131.
17. Nahar I, Al-Shemmeri M, Hussain M. Secondary hypertrophic osteoarthropathy: new insights on pathogenesis and management. Gulf J Oncolog. 2007;1(1):71-76.
18. Matucci-Cerinic M, Pignone A, Cagnoni M, et al. Is clubbing a growth disorder? Lancet. 1991;337(8738):434.
19. Silveri F, De Angelis R, Argentati F, et al. Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol. 1996;15:435-439. (Pubitemid 26319787)
20. Silveira L, Martinez-Lavin M, Pineda C, et al. Vascular endothelial growth factor in hypertrophic osteoarthropathy. Clin Exp Rheumatol. 2000;18:57-62. (Pubitemid 30102045)
21. Olan F, Portela M, Navarro C, et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol. 2004;31:614-616. (Pubitemid 38337628)
22. Hara Y, Matsuura Y, Takiguchi H, et al. Reversal of pulmonary hypertrophic osteoarthropathy in surgically treated lung cancer. Nihon Kokyuki Gakkai Zasshi. 2010;48(12):966-971.
23. Abe Y, Kurita S, Ohkubo Y, et al. A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res. 2002;22(6B):3485-3488. (Pubitemid 36132816)
24. Kim JH, Lee EB, Kim S, et al. A case of hypertrophic osteoarthropathy associated with epithelioid hemangioendothelioma. J Korean Med Sci. 2004;19(3):484-486. (Pubitemid 38859847)
25. Martínez-Lavín M, Pineda C. Digital clubbing. Lancet. 1990;336(8728):1444.
26. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15-35; discussion 35-36.
27. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997;79:233-269.
28. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029-1039.
29. Spicknall KE, Zirwas MJ, English JC 3rd. Clubbing: an update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance. J Am Acad Dermatol. 2005;52(6):1020-1028.
30. Martinez-Lavin M. Digital clubbing and hypertrophic osteoarthropathy: a unifying hypothesis. J Rheumatol. 1987;14(1):6-8.
31. Matucci-Cerinic M, Martinez-Lavin M, Rojo F, et al. von Willebrand factor antigen in hypertrophic osteoarthropathy. J Rheumatol. 1992;19(5):765-767.
32. Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet. 1987;19;2(8573):1434-1435.
33. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203:721-728. (Pubitemid 38714110)
34. Vazquez-Abad D, Martinez-Lavin M. Macrothrombocytes in the peripheral circulation of patients with cardiogenic hypertrophic osteoarthropathy. Clin Exp Rheumatol. 1991;9(1):59-62.
35. Fox SB, Day CA, Gatter KC. Association between platelet microthrombi and finger clubbing. Lancet. 1991;338(8762):313-314.
36. Poormoghim H, Hosseynian A, Javadi A. Primary hypertrophic osteoarthropathy. Rheumatol Int. 2012;32(3):607-610. Epub 2010 Dec 2.
37. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest. 1998;114(6):1535-1537. (Pubitemid 128487470)
38. Mito K, Maruyama R, Uenishi Y, et al. Hypertrophic pulmonary osteoarthropathy associated with non-small cell lung cancer demonstrated growth hormone-releasing hormone by immunohistochemical analysis. Intern Med. 2001;40(6):532-535. (Pubitemid 33611670)
39. Tay YK, Tham SN, Tey BH, et al. Pachydermoperiostosis (idiopathic hypertrophic osteoarthropathy) - a case report and review. Ann Acad Med Singapore. 1993;22(6):939-942.
40. Hussain W, Coulson IH. Hyperhidrosis in association with keratoderma and strikingly large hands and feet: a rare case of pachydermoperiostosis. Clin Exp Dermatol. 2010;35(3):e16-e17.
41. Benedek TG. Paraneoplastic digital clubbing and hypertrophic osteoarthropathy. Clin Dermatol. 1993;11(1):53-59. (Pubitemid 23191666)
42. Cathébras P, Gaultier JB, Charmion S, et al. Hypertrophic osteoarthropathy of the lower limbs. J Rheumatol. 2011;38(4):775-776.
43. King MM, Nelson DA. Hypertrophic osteoarthropathy effectively treated with zoledronic acid. Clin Lung Cancer. 2008;9(3):179-182. (Pubitemid 351880858)
44. Moralidis E, Gerasimou G, Theodoridou A, et al. Hypertrophic osteoarthropathy manifested with isolated calcaneal periostitis in bone scintigraphy. Ann Nucl Med. 2010;24(4):313-317.
45. Castori M, Sinibaldi L, Mingarelli R, et al. Pachydermoperiostosis: an update. Clin Genet. 2005;68:477-486. (Pubitemid 41748846)
46. Yao Q, Altman RD, Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum. 2009;38(6):458-466.
47. Le Roux BT. The presentation of bronchial carcinoma. Scot Med J. 1968;13:31-37.
48. Segal AM, Mackenzie AH. Hypertrophic osteoarthropathy: a 10-year retrospective analysis. Semin Arthritis Rheum. 1982;12:220-232.
49. Ooi A, Saad RA, Moorjani N, et al. Effective symptomatic relief of hypertrophic pulmonary osteoarthropathy by video-assisted throacic surgery truncal vagotomy. Ann Thorac Surg. 2007;83:684-685. (Pubitemid 46135409)
50. Atkinson MK, McElwain TJ, Peckham MJ, et al. Hypertrophic pulmonary osteoarthropathy in Hodgkin's disease: reversal with chemotherapy. Cancer. 1976;28:1729-1734.
51. Poanta L, Parasca I, Fazakas E, et al. Paraneoplastic hypertrophic osteoarthropathy: evaluation at 25 years after pneumectomy. Pol Arch Med Wewn. 2009;119(9):603-606.
52. Akizuki M, Homma M. Amelioration of secondary hypertrophic osteoarthropathy following tumor resection in a patient with primary lung cancer. Ryumachi [Rheum]. 1991;31:311-316, discussion 316-317.
53. Huaux JP, Geubel A, Maldague B, et al. Hypertrophic osteoarthropathy related to end stage cholestatic cirrhosis: reversal after liver transplantation. Ann Rheum Dis. 1987;46:342-345. (Pubitemid 17051228)
54. Kaymakcalan H, Sequeria W, Barretta T, et al. Hypertrophic osteoarthropathy with myogenic tumors of the esophagus. Am J Gastroenterol. 1980;74:17-20. (Pubitemid 10020819)
55. Frand M, Koren G, Rubinstein Z. Reversible hypertrophic osteoarthropathy associated with cyanotic congenital heart disease. Am J Dis Child. 1982;136:687-689. (Pubitemid 12096956)
56. Taillandier J, Alemanni M, Samuel D, et al. Hepatic hypertrophic osteoarthropathy: the value of liver transplantation. Clin Exp Rheumatol. 1998;16(1):80-81. (Pubitemid 28133489)
57. Kozak KR, Milne GL, Morrow JD, et al. Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2- derived prostaglandin E2. Nat Clin Pract Rheumatol. 2006;2:452-456. (Pubitemid 44203829)
58. Blackwell N, Bangham L, Hughes M, et al. Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac. Thorax. 1993;48:401. (Pubitemid 23126312)
59. Leung FW, Williams AJ, Fan P. Indomethacin therapy for hypertrophic pulmonary osteoarthropathy in patients with bronchogenic carcinoma. West J Med. 1985;142:345-347. (Pubitemid 15091364)
60. Penson RT, Rudd RM. Commentary: octreotide and hypertrophic pulmonary osteoarthropathy. Thorax. 1997;52(3):297-298. (Pubitemid 27128187)
61. Johnson SA, Spiller PA, Faull CM. Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide. Thorax. 1997;52(3):298-299. (Pubitemid 27128188)
62. Angel-Moreno Maroto A, Martínez-Quintana E, et al. Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology (Oxford). 2005;44(10):1326-1327. (Pubitemid 41487974)
63. Suzuma T, Sakurai T, Yoshimura G, et al. Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs. 2001;12:731-734. (Pubitemid 33001186)
64. Garske LA, Bell SC: Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest. 2002;121:1363-1364. (Pubitemid 34280469)
65. Bhansali A, Singh R, Sriraam M, et al. Pachydermoperiostitis and bisphosphonates. J Assoc Physicians India. 2006;54:340. (Pubitemid 43528622)
66. Guyot-Drouot MH, Solau-Gervais E, Cortet B, et al. Rheumatologic manifestations of pachydermoperiostosis and preliminary experience with bisphosphonates. J Rheumatol. 2000;27:2418-2423.
67. Speden D, Nicklason F, Francis H, et al. The use of pamidronate in hypertrophic osteoarthropathy (HPOA). Aust NZ J Med. 1997;27:307-310. (Pubitemid 27306098)
68. Hayashi M, Sekikawa A, Saijo A, et al. Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma. Anticancer Res. 2005;25(3c):2435-2438. (Pubitemid 41044727)
69. Imai H, Tomizawa Y, Ishihara S, et al. A case of pulmonary hypertrophic osteoarthropathy associated with primary lung cancer in a young adult successfully treated with gefitinib. Nihon Kokyuki Gakkai Zasshi. 2007;45(2):189-193.
70. Janku F, Garrido-Laguna I, Petruzelka LB, et al. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1601-1612.
71. Ghosn S, Uthman I, Dahdah M, et al. Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A. J Am Acad Dermatol. 2010;63(6):1036-1041.